APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Outlook and Growth Opportunities 2026

Report ID 173985000422 December 2025199 pages

Choose your research edition.

Industry ResearchDipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market include Takeda, Novartis, Merck, Eli Lilly, AstraZeneca, Mitsubishi Tanabe Pharma and Boehringer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dipeptidyl Peptidase IV (DPP-IV) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Company

Takeda

Novartis

Merck

Eli Lilly

AstraZeneca

Mitsubishi Tanabe Pharma

Boehringer

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Type

Vildagliptin

Saxagliptin

Sitagliptin

Linagliptin

Others

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dipeptidyl Peptidase IV (DPP-IV) Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Dipeptidyl Peptidase IV (DPP-IV) Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors industry.

Chapter 3: Detailed analysis of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Trends Table 2. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Drivers Table 3. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Opportunities and Challenges Table 4. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Restraints Table 5. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Average Price (US$/ton) of Company (2021-2026) Table 10. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company, Product Type & Application Table 13. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vildagliptin Table 18. Significant Companies of Saxagliptin Table 19. Significant Companies of Sitagliptin Table 20. Significant Companies of Linagliptin Table 21. Significant Companies of Others Table 22. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 23. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type (2021-2026) & (k tons) Table 24. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type (2027-2032) & (k tons) Table 25. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Type (2021-2026) Table 26. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Type (2027-2032) Table 27. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type (2021-2026) Table 31. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Pharmacies Table 33. Significant Companies of Online Pharmacies Table 34. Significant Companies of Retail Pharmacies Table 35. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 36. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application (2021-2026) & (k tons) Table 37. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application (2027-2032) & (k tons) Table 38. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Application (2021-2026) Table 39. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Application (2027-2032) Table 40. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application (2021-2026) Table 44. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application (2027-2032) Table 45. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 46. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2021-2026) & (k tons) Table 47. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2027-2032) & (k tons) Table 49. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Region (2027-2032) Table 50. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Region (2021-2026) Table 53. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Region (2027-2032) Table 55. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Average Price (US$/ton) by Region (2021-2026) Table 56. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Average Price (US$/ton) by Region (2027-2032) Table 57. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026) & (k tons) Table 60. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2021-2026) Table 61. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032) & (k tons) Table 62. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2027-2032) Table 63. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Market Share by Country (2021-2026) Table 65. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Market Share by Country (2027-2032) Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 70. Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 71. Takeda Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 75. Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 76. Novartis Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 80. Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 81. Merck Recent Development Table 82. Eli Lilly Company Information Table 83. Eli Lilly Business Overview Table 84. Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 85. Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 86. Eli Lilly Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 90. AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Mitsubishi Tanabe Pharma Company Information Table 93. Mitsubishi Tanabe Pharma Business Overview Table 94. Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 95. Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 96. Mitsubishi Tanabe Pharma Recent Development Table 97. Boehringer Company Information Table 98. Boehringer Business Overview Table 99. Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 100. Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 101. Boehringer Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Distributors List Table 105. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Image Figure 2. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (2021-2032) & (k tons) Figure 5. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vildagliptin Image Figure 10. Saxagliptin Image Figure 11. Sitagliptin Image Figure 12. Linagliptin Image Figure 13. Others Image Figure 14. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Type (2021-2032) Figure 17. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 24. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Application (2021-2032) Figure 26. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application (2021-2032) Figure 29. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 30. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. South America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Vildagliptin
  • Saxagliptin
  • Sitagliptin
  • Linagliptin
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Novartis
  • Merck
  • Eli Lilly
  • AstraZeneca
  • Mitsubishi Tanabe Pharma
  • Boehringer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Dynamics
  1. 2.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Trends
  2. 2.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Drivers
  3. 2.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Restraints
3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Company
  1. 3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Product Type and Application
  8. 3.8 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Type
  1. 4.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Type Introduction
  2. 4.1.1 Vildagliptin
  3. 4.1.2 Saxagliptin
  4. 4.1.3 Sitagliptin
  5. 4.1.4 Linagliptin
  6. 4.1.5 Others
  7. 4.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type
  8. 4.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type
  12. 4.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Type (2021-2032)
  14. 4.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type (2021-2032)
5 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Application
  1. 5.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application
  6. 5.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application
  10. 5.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application (2021-2032)
6 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Mitsubishi Tanabe Pharma
  32. 8.6.1 Mitsubishi Tanabe Pharma Company Information
  33. 8.6.2 Mitsubishi Tanabe Pharma Business Overview
  34. 8.6.3 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  36. 8.6.5 Mitsubishi Tanabe Pharma Recent Developments
  37. 8.7 Boehringer
  38. 8.7.1 Boehringer Company Information
  39. 8.7.2 Boehringer Business Overview
  40. 8.7.3 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  42. 8.7.5 Boehringer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Value Chain Analysis
  2. 9.1.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Mode & Process
  6. 9.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Distributors
  9. 9.2.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst